Chronic Hepatitis B Clinical Trial
Official title:
A Phase 1/1b, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Subcutaneously Administered ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Ascending Doses in Healthy Volunteers (Part 1) and Subjects With Chronic Hepatitis B (Part 2), and Multiple Doses in Subjects With Chronic Hepatitis B (Part 3)
Verified date | March 2024 |
Source | Aligos Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A randomized study of ALG-125755 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single doses in healthy volunteers, and single and multiple doses in CHB subjects
Status | Terminated |
Enrollment | 57 |
Est. completion date | June 15, 2023 |
Est. primary completion date | June 15, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria for All Subjects: 1. Female subjects must have a negative serum pregnancy test at screening 2. Subjects must have a 12-lead electrocardiogram (ECG) that meets the protocol criteria Inclusion Criteria for Healthy Subjects: 1. Male or female between 18 and 55 years of age, extremes included. 2. Subjects must have a body mass index (BMI) of 18.0 to 32.0 kg/m2, extremes included. Inclusion Criteria for CHB Subjects (Parts 2 and 3): 1. Subjects must be 18 to 70 years of age, inclusive of extremes. 2. Subjects may have a BMI of 18.0 to 35.0 kg/m2, extremes included. 3. For virally suppressed subjects, must be currently receiving HBV NA treatment for =6 months prior to screening. For currently not treated or treatment naïve subjects, must have never received treatment OR have not been on treatment within 6 months prior to randomization Exclusion Criteria for All Subjects: 1. Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results' interpretation 2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or clinical evidence at screening of significant or unstable cardiac disease etc. 3. Subjects with a history of clinically significant drug allergy 4. Subject with current or history of clinically significant (as determined by the Investigator) skin disease requiring intermittent or chronic treatment 5. Excessive use of alcohol defined as regular consumption of =14 standard drinks/week for women and =21 standard drinks/week for men 6. Subjects with Hepatitis A, B, C, D, E or HIV-1/HIV-2 infection or acute infections such as SARS- CoV-2 infection Exclusion Criteria for Healthy Volunteers (Part 1): 1. Unwilling to abstain from alcohol use for 48 hours prior to start of study through end of study follow up. 2. Subjects with renal dysfunction [e.g., estimated creatinine clearance <90 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] Exclusion criteria for CHB subjects (Parts 2 and 3): 1. Subjects who are positive for anti-HBs antibodies. 2. Subject with any history or current evidence of hepatic decompensation such as: variceal bleeding, spontaneous bacterial peritonitis, ascites, hepatic encephalopathy, or active jaundice (within the last year). 3. History or current evidence of cirrhosis. 4. Subjects with liver fibrosis that is classified as Metavir Score =F3 liver disease 5. Subjects must have absence of signs of hepatocellular carcinoma |
Country | Name | City | State |
---|---|---|---|
Bulgaria | MBAL Sveta Sofia EOOD, Dept of Internal Medicine with Gastroenterology Section | Sofia | |
Moldova, Republic of | PMSI Republican Clinical Hospital "t. Mosneaga", ARENSIA Exploratory Medicine Phase 1 Unit | Chisinau | |
New Zealand | New Zealand Clinical Research | Auckland | |
Romania | National Institute for Infection Diseases, ARENSIA Exploratory Medicine S.R.L. | Bucharest |
Lead Sponsor | Collaborator |
---|---|
Aligos Therapeutics |
Bulgaria, Moldova, Republic of, New Zealand, Romania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and severity of treatment emergent adverse events as assessed by DAIDS v2.1 of various doses of ALG-125755 in HV subjects and CHB subjects | Up to 32 days for Part 1 | ||
Primary | Incidence and severity of treatment emergent adverse events as assessed by DAIDS v2.1 | Up to 52 days for Part 2 | ||
Primary | Incidence and severity of treatment emergent adverse events as assessed by DAIDS v2.1 | Up to 616 days for Part 3 | ||
Secondary | Maximum plasma concentration (Cmax) | Pharmacokinetic parameters of ALG-125755 in plasma | Predose (0 hours) up to 616 days | |
Secondary | Area under the concentration time curve [AUC] | Pharmacokinetic parameters of ALG-125755 in plasma | Predose (0 hours) up to 616 days | |
Secondary | Time to maximum plasma concentration [Tmax] | Pharmacokinetic parameters of ALG-125755 in plasma | Predose (0 hours) up to 616 days | |
Secondary | Antiviral activity of ALG-125755 as measured by quantitative changes in serum | Pharmacokinetic parameters of ALG-125755 in plasma | Predose (0 hours) up to 616 days | |
Secondary | Minimum plasma concentration (Cmin) | Pharmacokinetic parameters of ALG-125755 in plasma | Predose (0 hours) up to 616 days | |
Secondary | Change in HBsAg from baseline through up to 112 days from last dose in multiple dose HBV infected subjects | screening to up to 112 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04496882 -
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
|
Phase 4 | |
Completed |
NCT04083716 -
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT03038802 -
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
|
Phase 1/Phase 2 | |
Completed |
NCT05310487 -
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT06070051 -
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
|
Phase 1 | |
Terminated |
NCT05001022 -
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
|
Phase 1 | |
Recruiting |
NCT04139850 -
The Establishment of Korean Hepatitis B Patients Cohort
|
||
Recruiting |
NCT05343481 -
Efficacy of VTP-300 in Chronic Hepatitis B Infection
|
Phase 2 | |
Not yet recruiting |
NCT05490836 -
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
|
N/A | |
Recruiting |
NCT04543565 -
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
|
Phase 3 | |
Active, not recruiting |
NCT02894918 -
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
|
Phase 4 | |
Not yet recruiting |
NCT02793791 -
Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients
|
N/A | |
Recruiting |
NCT02287857 -
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
|
N/A | |
Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
Recruiting |
NCT01491295 -
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
|
Phase 4 | |
Terminated |
NCT01872988 -
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
|
Phase 3 | |
Recruiting |
NCT01487876 -
Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients
|
Phase 2 | |
Not yet recruiting |
NCT01436539 -
Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients
|
Phase 4 | |
Completed |
NCT01531166 -
A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon
|
N/A | |
Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A |